| 000 | 01820 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517173120.0 | ||
| 264 | 0 | _c20171023 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a1879-0852 | ||
| 024 | 7 |
_a10.1016/j.ejca.2017.08.014 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMichot, Jean-Marie | |
| 245 | 0 | 0 |
_aChallenges and perspectives in the immunotherapy of Hodgkin lymphoma. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _c11 2017 |
||
| 300 |
_a67-77 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aHodgkin Disease _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReed-Sternberg Cells _xdrug effects |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Escape _xdrug effects |
| 650 | 0 | 4 | _aTumor Microenvironment |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLazarovici, Julien | |
| 700 | 1 | _aGhez, David | |
| 700 | 1 | _aDanu, Alina | |
| 700 | 1 | _aFermé, Christophe | |
| 700 | 1 | _aBigorgne, Amélie | |
| 700 | 1 | _aRibrag, Vincent | |
| 700 | 1 | _aMarabelle, Aurélien | |
| 700 | 1 | _aAspeslagh, Sandrine | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 85 _gp. 67-77 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejca.2017.08.014 _zAvailable from publisher's website |
| 999 |
_c27547845 _d27547845 |
||